HIF1A and neoplasm: To evaluate the effect of single and combined inhibition of HIF-1α and TGF-β specifically in tumor cells in vivo, we generated a series of MDA-MB-231 cell lines which stably expressed either HIF-1α shRNA alone or in combination with a dominant-negative TGF-β type II receptor (DNRII).